• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Pluristem Life Systems, Inc. Receives $1.1 Million From Exercise of Warrants

Posted on: Wednesday, 4 April 2007, 09:00 CDT

Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of cell therapy products for a variety of indications, said that as of Friday, March 30, 2007 it has received $1.1 million from the exercise of approximately 15 million warrants at an exercise price of $0.075. This represents exercise of more than 25% of Pluristem's outstanding listed warrants as of March 30, 2007.

Zami Aberman, Pluristem CEO, stated: "Our shareholders continue to show support and confidence in our future. Our stronger working capital position allows us to complete preparations for our application to the Food & Drug Administration (FDA) to conduct clinical trials for our first product, PLX-I, for Leukemia, planned later this year. We will begin investigating the use of our PLX cells for other disease indications and fund our previously announced intent to enlarge our good manufacturing practices (GMP) compliant production facility, supporting our goal to be a fully integrated pharmaceutical company."

About Pluristem

Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor termed the PluriX™ that mimics different naturally occurring physiological environments. Pluristem expects its first product, PLX-I, will be involved as an efficient and superior alternative to the standard procedure of bone marrow transplantation (BMT). PLX-I is intended to target a critical global shortfall of matched tissue for BMT since BMT is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release, include that our stronger working capital position allows us to complete preparations for our application to the Food & Drug Administration (FDA) to conduct clinical trials for our first product; PLX-I, for Leukemia, planned later this year; that we will begin investigating the use of our PLX cells for other disease indications; that we will fund our previously announced intent to enlarge our good manufacturing practices (GMP) compliant production facility supporting our goal to be a fully integrated pharmaceutical company.

Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Source: Business Wire

More News in this Category